Biotech »

3D’s TeloView can identify Alzheimer’s patients

3D’s TeloView can identify Alzheimer’s patients

Alpha Stox March 21, 2017 Comments Off

Mr. Hugh Rogers reports 3D SIGNATURES’ TELOVIEW SOFTWARE IDENTIFIES AND STAGES PATIENTS WITH ALZHEIMER’S DISEASE FROM A CHEEK SWAB 3D Signatures Inc. has provided clinical study results which confirm that based on a swab

Read More »
RepliCel’s baldness treatment shown to be safe in trial

RepliCel’s baldness treatment shown to be safe in trial

Alpha Stox March 14, 2017 Comments Off

Mr. Lee Buckler reports REPLICEL’S PHASE 1 CLINICAL TRIAL FOR HAIR LOSS SUCCEEDS IN MEETING PRIMARY ENDPOINTS RepliCel Life Sciences Inc. has successfully completed its first-in-human clinical study of the company’s autologous cell therapy

Read More »
Revive appoints Wang as scientific adviser

Revive appoints Wang as scientific adviser

Alpha Stox March 8, 2017 Comments Off

Mr. Craig Leon reports REVIVE THERAPEUTICS APPOINTS DR. YANLIN WANG, MD, PHD, AS SCIENTIFIC ADVISOR FOR CANNABINOID-BASED THERAPEUTICS TARGETING KIDNEY DISEASE Dr. Yanlin Wang, MD, PhD, will join Revive Therapeutics Ltd. as a scientific

Read More »
RepliCel hires FreeMind to seek research financing

RepliCel hires FreeMind to seek research financing

Alpha Stox March 7, 2017 Comments Off

Mr. Lee Buckler reports REPLICEL PURSUES NON-DILUTING GRANT FUNDING TO ACCELERATE VALUE CREATION AND COMMERCIALIZATION RepliCel Life Sciences Inc. has retained The FreeMind Group, a premier international firm that assists life science organizations in

Read More »
Revive Therapeutics Announces Initiation of Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases

Revive Therapeutics Announces Initiation of Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases

Alpha Stox March 1, 2017 Comments Off

TORONTO, ONTARIO–(Marketwired – March 1, 2017) - Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical

Read More »
RepliCel closes $3.16-million in private placements

RepliCel closes $3.16-million in private placements

Alpha Stox February 24, 2017 Comments Off

Mr. Lee Buckler reports REPLICEL LIFE SCIENCES ANNOUNCES CLOSING OF BROKERED AND NON-BROKERED PRIVATE PLACEMENT RepliCel Life Sciences Inc. has completed its financing announced on Feb. 7, 2017, which consisted of a brokered private

Read More »
Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

Alpha Stox February 16, 2017 Comments Off

TORONTO, ONTARIO–(Marketwired – Feb. 16, 2017) - Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical

Read More »
3D appoints Glorikian to business advisory board

3D appoints Glorikian to business advisory board

Alpha Stox February 15, 2017 Comments Off

Mr. Jason Flowerday reports 3D SIGNATURES INC. ADDS MEDICAL DIAGNOSTIC EXPERT TO BUSINESS ADVISORY BOARD Harry Glorikian has joined 3D Signatures Inc.’s business advisory board. Mr. Glorikian has over 30 years of private and

Read More »
Revive starts phase II cystinuria clincal study

Revive starts phase II cystinuria clincal study

Alpha Stox February 7, 2017 Comments Off

Mr. Craig Leon reports REVIVE THERAPEUTICS ANNOUNCES INITIATION OF A PHASE 2 STUDY OF REV-004 (BUCILLAMINE) IN CYSTINURIA Revive Therapeutics Ltd. has initiated a phase II clinical study in patients with cystinuria in the

Read More »
3D Signatures provides details on Kilmer Lucas hire

3D Signatures provides details on Kilmer Lucas hire

Alpha Stox January 16, 2017 Comments Off

Mr. Stephen Kilmer reports 3D SIGNATURES INC. PROVIDES FURTHER DETAIL ON KILMER LUCAS ENGAGEMENT In addition to its press release on Dec. 22, 2016, 3D Signatures Inc. has provided further details regarding its engagement

Read More »
Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1